Sander Martijn Job van Kuijk

Sander Martijn Job van Kuijk

Auto-generated profile, based on publicly available information

Sander Martijn Job van Kuijk

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2019 in European Heart Journal
Verified
Journal Article
Open access
EWE P J Petra Wijtvliet
E P J Petra Wijtvliet
RTRobert G Tieleman
Robert G Tieleman
IGIsabelle C van Gelder
Isabelle C van Gelder
NPNikki A H A Pluymaekers
Nikki A H A Pluymaekers
MRMichiel Rienstra
Michiel Rienstra
RIRACE 4 Investigators
RACE 4 Investigators
Background: Nurse-led integrated care is expected to improve outcome of patients with atrial fibrillation compared with usual-care provided by a medical specialist. Methods and results: We randomized 1375 patients with atrial fibrillation (64 ± 10 years, 44% women, 57% had CHA2DS2-VASc ≥ 2) to receive nurse-led care or usual-care. Nurse-led care was provided by specialized nurses using a decision-support tool, in consultation with the cardiologist. The primary endpoint was a composite of cardiovascular death and cardiovascular hospital admissions. Of 671 nurse-led care patients, 543 (81%) received anticoagulation in full accordance with the guidelines against 559 of 683 (82%) usual-care patients. The cumulative adherence to guidelines-based recommendations was 61% under nurse-led care and 26% under usual-care. Over 37 months of follow-up, the primary endpoint occurred in 164 of 671 patients (9.7% per year) under nurse-led care and in 192 of 683 patients (11.6% per year) under usual-care [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.69 to 1.04, P = 0.12]. There were 124 vs. 161 hospitalizations for arrhythmia events (7.0% and 9.4% per year), and 14 vs. 22 for heart failure (0.7% and 1.1% per year), respectively. Results were not consistent in a pre-specified subgroup analysis by centre experience, with a HR of 0.52 (95% CI 0.37–to 0.71) in four experienced centres and of 1.24 (95% CI 0.94–1.63) in four less experienced centres (P for interaction <0.001). Conclusion: Our trial failed to show that nurse-led care was superior to usual-care. The data suggest that nurse-led care by an experienced team could be clinically beneficial (ClinicalTrials.gov NCT01740037). Trial Registration number: ClinicalTrials.gov (NCT01740037).

26 December 2013 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
ESEnc Schoorel
Enc Schoorel
SKSmj van Kuijk
Smj van Kuijk
SMS Melman
S Melman
JNJg Nijhuis
Jg Nijhuis
LSLjm Smits
Ljm Smits
HSHcj Scheepers
Hcj Scheepers
Objective: To develop and internally validate a model that predicts the outcome of an intended vaginal birth after caesarean (VBAC) for a Western European population that can be used to personalise counselling for deliveries at term.Design: Registration‐based retrospective cohort study.Setting: Five university teaching hospitals, seven non‐university teaching hospitals, and five non‐university non‐teaching hospitals in the Netherlands.Population: A cohort of 515 women with a history of one caesarean section and a viable singleton pregnancy, without a contraindication for intended VBAC, who delivered at term.Methods: Potential predictors for a vaginal delivery after caesarean section were chosen based on literature and expert opinions. We internally validated the prediction model using bootstrapping techniques.Main outcome measures: Predictors for VBAC. For model validation, the area under the receiver operating characteristic curve (AUC) for discriminative capacity and calibration‐per‐risk‐quantile for accuracy were calculated.Results: A total of 371 out of 515 women had a VBAC (72%). Variables included in the model were: estimated fetal weight greater than the 90th percentile in the third trimester; previous non‐progressive labour; previous vaginal delivery; induction of labour; pre‐pregnancy body mass index; and ethnicity. The AUC was 71% (95% confidence interval, 95% CI = 69–73%), indicating a good discriminative ability. The calibration plot shows that the predicted probabilities are well calibrated, especially from 65% up, which accounts for 77% of the total study population.Conclusion: We developed an appropriate Western European population‐based prediction model that is aimed to personalise counselling for term deliveries.

1 September 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
JHJ. Haumann
J. Haumann
JGJ.W. Geurts
J.W. Geurts
SKS.M.J. van Kuijk
S.M.J. van Kuijk
BKB. Kremer
B. Kremer
EJE.A. Joosten
E.A. Joosten
MEMarieke H.J. Van den Beuken-van Everdingen
Marieke H.J. Van den Beuken-van Everdingen

1 August 2013 in Hypertension
Verified
Journal Article
Closed access
PDF file
CGChahinda Ghossein-Doha
Chahinda Ghossein-Doha
LPLouis Peeters
Louis Peeters
SHSanne van Heijster
Sanne van Heijster
SKSander van Kuijk
Sander van Kuijk
JSJulia Spaan
Julia Spaan
MSMarc Spaanderman
Marc Spaanderman
Preeclampsia is associated with a 4-fold higher risk for developing remote chronic hypertension. Preeclampsia is accompanied by left ventricular hypertrophy and decreased diastolic function, which may or may not resolve postpartum. We tested the hypothesis that increased measures of cardiac geometry and decreased cardiac function persisting for ≥6 months postpartum in normotensive women with a history of preeclampsia precede the development of later chronic hypertension. Formerly preeclamptic women (n=652) underwent echocardiography at 9 months (range, 6–19) postpartum. We excluded women with preexisting hypertension (n=42), hypertension at the postpartum screening (n=133), and those that did not return any checklist (n=128). Eventually, 349 women were included. Remote health was evaluated by a biennially checklist. We used Cox regression for analysis. Twenty-seven (8%) normotensive women had developed chronic hypertension during a medium follow-up period of 6 years. At screening they differed from their counterparts who remained normotensive by hazard ratio for left ventricular mass index (1.11; 95% confidence interval [CI], 1.03–1.18), diastolic blood pressure (1.13; 95% CI, 1.06–1.20), systolic blood pressure (1.07; 95% CI, 1.02–1.11), mean arterial pressure (1.11; 95% CI, 1.05–1.18), heart rate (1.05; 95% CI, 1.01–1.10), and E/A ratio (0.22; 95% CI, 0.06–0.85). Backward stepwise analysis showed independent hazard ratio for left ventricular mass index and diastolic blood pressure 1.08 (95% CI, 1.01–1.16) and 1.13 (95% CI, 1.06–1.21), respectively. In conclusion, the development of later chronic hypertension in initially normotensive formerly preeclamptic women is preceded by increased left ventricular mass index and diastolic blood pressure at postpartum screening.

3 February 2022 in Critical Care Medicine
Verified
Journal Article
Closed access
AWAnne Willers
Anne Willers
JSJustyna Swol
Justyna Swol
HBHergen Buscher
Hergen Buscher
ZMZoe McQuilten
Zoe McQuilten
SKSander M. J. van Kuijk
Sander M. J. van Kuijk
JTJoseph Tonna
Joseph Tonna
OBJECTIVES: Data about inhospital outcomes in bleeding complications during extracorporeal life support (ECLS) have been poorly investigated. DESIGN: Retrospective observational study. SETTING: Patients reported in Extracorporeal Life Support Organization Registry. PATIENTS: Data of 53.644 adult patients (greater than or equal to 18 yr old) mean age 51.4 ± 15.9 years, 33.859 (64.5%) male supported with single ECLS run between 01.01.2000 and 31.03.2020, and 19.748 cannulated for venovenous (V-V) ECLS and 30.696 for venoarterial (V-A) ECLS. INTERVENTIONS: Trends in bleeding complications, bleeding risk factors, and mortality. MEASUREMENT AND MAIN RESULTS: Bleeding complications were reported in 14.786 patients (27.6%), more often in V-A ECLS compared with V-V (30.0% vs 21.9%; p < 0.001). Hospital survival in those who developed bleeding complications was lower in both V-V ECLS (49.6% vs 66.6%; p < 0.001) and V-A ECLS (33.9 vs 44.9%; p < 0.001). Steady decrease in bleeding complications in V-V and V-A ECLS was observed over the past 20 years (coef., –1.124; p < 0.001 and –1.661; p < 0.001). No change in mortality rates was reported over time in V-V or V-A ECLS (coef., –0.147; p = 0.442 and coef., –0.195; p = 0.139). Multivariate regression revealed advanced age, ecls duration, surgical cannulation, renal replacement therapy, prone positioning as independent bleeding predictors in v-v ecls and female gender, ecls duration, pre-ecls arrest or bridge to transplant, therapeutic hypothermia, and surgical cannulation in v-a ecls. CONCLUSIONS: A steady decrease in bleeding over the last 20 years, mostly attributable to surgical and cannula-site–related bleeding has been found in this large cohort of patients receiving ECLS support. However, there is not enough data to attribute the decreasing trends in bleeding to technological refinements alone. Especially reduction in cannulation site bleeding is also due to changes in timing, patient selection, and ultrasound guided percutaneous cannulation. Other types of bleeding, such as CNS, have remained stable, and overall bleeding remains associated with a persistent increase in mortality.

10 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
MEMarieke H.J. Van den Beuken-van Everdingen
Marieke H.J. Van den Beuken-van Everdingen
SKSander M. J. Van Kuijk
Sander M. J. Van Kuijk
DJDaisy Janssen
Daisy Janssen
EJElbert A.J. Joosten
Elbert A.J. Joosten
Despite increased attention to cancer pain, pain prevalence in patients with cancer has not improved over the last decade and one third of cancer patients on anticancer therapy and half of patients with advanced disease still suffer from moderate to severe pain. In this review, we explore the possible reasons for the ongoing high prevalence of cancer pain and discuss possible future directions for improvement in personalised pain management. Among possible reasons for the lack of improvement are: Barriers for patients to discuss pain with clinicians spontaneously; pain measurement instruments are not routinely used in daily practice; limited knowledge concerning the assessment of undertreatment; changes in patients’ characteristics, including the ageing of the population; lack of significant improvement in the treatment of neuropathic pain; limitations of pharmacological treatment and lack of evidence-based nonpharmacological treatment strategies. In order to improve cancer pain treatment, we recommend: (1) Physicians proactively ask about pain and measure pain using assessment instruments; (2) the development of an optimal tool measuring undertreatment; (3) educational interventions to improve health care workers’ skills in pain management; (4) the development of more effective and personalised pharmacological and nonpharmacological pain treatment.